Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST vismodegib substudy in advanced solid cancers with PTCH1 or SMO mutations
ACTRN12618000281291Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in cancer and Nonhematologic neoplasms, sponsored by The University of Sydney. Primary endpoint: Disease control / objective tumor response. Started Dec 2018; status: completed.
02
Drugs
vismodegib
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12618000281291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000281291.